Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Presentation & Pre-screening of the control group / reminiscence group Patient/resident pre-screening team meeting for the study Explanation and proposal of the study to patients and their families Signature of resident/patient and family consents Audit of inclusion and non-inclusion criteria Inclusion Medical advice for VR Clinical interview with the family or legal guardian for an accurate life history + an anamnesis interview (psychologist or doctor) with the patient or resident.
Creation of video contents Creation of personalized video contents Clinical scales review Evaluation of the number of psychotropic molecules prescribed (coordinating doctor, general practitioner, geriatrician)
Each subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families).
The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation.
The subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.) with a different virtual environment every 3 weeks.
During the session, note will be taken on the subject's speech. The session will also be filmed and/or recorded with a prior signed agreement by the patient or his representative.
- Last session (S6) Review of clinical scales (re-testing) Re-evaluation of drug prescriptions
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| personalized video | Experimental | Each subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families). |
|
| generic vidéo | Active Comparator | The subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| virtual reality session | Procedure | The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks. The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation. |
| Measure | Description | Time Frame |
|---|---|---|
| Depression and anxiety assessment | assessment with Hamilton scale | change of Hamilton score between inclusion and 6 weeks (before and after therapy) |
| Measure | Description | Time Frame |
|---|---|---|
| psychotropic drugs consumption | assessment of psychotropic drugs consumption | change in psychotropic drugs consumption between inclusion and 6 weeks (before and after therapy) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Olivier guerin.o@chu-nice.fr, PU-PH | Nice University Hospital, Gerontology Department | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Nice | Nice | 06000 | France | |||
| EPHAD Ancilla |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D019964 | Mood Disorders |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
The virtual reality sessions will take place twice a week during 6 weeks. Each subject will have two different virtual environment. The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation.
Not provided
Not provided
Not provided
Not provided
|
| Nice |
| France |
| EPHAD Clos de Cimiez | Nice | France |
| Hopital privé Gériatrique Les Sources | Nice | France |
| D024801 |
| Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |